Neuro/Images. Kayser-Fleischer corneal ring.

geminovascular activation in cluster headache. Brain 1994; 117:427–434. 23. May A, Bahra A, Buchel C, Frackowiak RSJ, Goadsby PJ. Hypothalamic activation in cluster headache attacks. Lancet 1998;351:275–278. 24. May A, Ashburner J, Buchel C, et al. Correlation between structural and functional changes in brain in an idiopathic headache syndrome. Nat Med 1999;5:836–838. 25. Kudrow L. Response of cluster headache attacks to oxygen inhalation. Headache 1981;21:1–4. 26. Friedman AP, Mikropoulos HE. Cluster headache. Neurology 1958;8:653–663. 27. Ibraheem JJ, Paalzow L, Tfelt-Hansen P. Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers. Br J Clin Pharmacol 1983;16:695–699. 28. Tfelt-Hansen P, Johnson ES. Ergotamine. In: Olesen J, TfeltHansen P, Welch KMA, eds. The headaches. New York: Raven Press, 1993:313–322. 29. Kitrelle JP, Grouse DS, Seybold ME. Cluster headache: local anesthetic abortive agents. Arch Neurol 1985;42:496–498. 30. Barre F. Cocaine as an abortive agent in cluster headache. Headache 1982;22:69–73. 31. Visser WH, Klein KB, Cox RC, Jones D, Ferrari M. 311C90, a new central and peripherally acting 5HT-1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled dose-range finding study. Neurology 1996; 46:522–526. 32. Rapoport AM, Ramadan NM, Adelman JU, et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. Neurology 1997;49:1210–1218. 33. MaassenVanDenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998;98:25–30.